조산 및 PROM(조기양막파열) 검사 시장은 조산 및 양막파열의 진단과 치료에 초점을 맞추었습니다. 조산율 증가와 진단 기술의 발전이 성장의 원동력이 되고 있습니다. 신흥 시장은 헬스케어의 중요성에 대한 인식이 높아짐에 따라 성장하고 있습니다. 이에 따라 시장 규모는 2024년 23억 9,000만 달러를 돌파하고 2032년에는 약 41억 1,000만 달러에 달할 것으로 예측됩니다.
이 시장 시장은 조기 발견 및 조기 관리를 위한 새로운 검사를 개발하고 있습니다. 비침습적 시술과 현장 진단이 미래를 정의하고 있습니다. 의료 전문가들이 환자의 예후를 개선하고 조산 문제를 예방하기 위해 노력함에 따라 정확하고 신속한 진단에 대한 수요가 시장 성장을 주도하고 있습니다. 조산 및 PROM 검사에 대한 수요가 증가함에 따라 2026-2032년 연평균 7.76% 시장 성장이 예상됩니다.
조산 및 PROM 검사 시장 정의/개요
조산은 임신 37주 이전에 분만하는 것으로 정의되며, 아기의 건강상의 합병증을 유발할 수 있습니다. PROM 검사 진통이 시작되기 전에 양막낭이 파열되는 양막조기파열(PROM)을 평가하여 위험을 평가하고 산모와 아기 모두 어려움을 겪지 않도록 관리를 안내합니다.
조산 및 PROM 검사는 고위험 임신을 발견하는 데 도움이 됩니다. 조산 검사는 조기 분만 가능성을 판단하고, PROM 검사는 막 파열을 감지하여 감염을 예방하고 조산 위험을 관리하는 데 도움이 됩니다. 두 검사 모두 조기 개입과 영아 예후 개선에 필수적입니다.
조산 및 PROM 검사의 향후 응용은 조기 발견 증가, 표적 치료의 안내, 치료 접근법의 개별화 등을 포함합니다. 조산율과 그에 따른 어려움을 최소화하기 위해 예측 바이오마커를 결합하고, 비침습적 진단법을 확립하고, 임상 가이드라인을 개정함으로써 진전을 이룰 수 있을 것으로 보입니다.
2021년 미국의 조산율은 2020년 10.1%에서 10.5%로 증가하여 거의 10명 중 1명이 조산아로 태어날 것이며, 2014년부터 2021년까지 조산율은 12% 증가하여 매년 전 세계적으로 약 1,500만 명의 아기가 조산으로 태어날 것으로 예측됩니다. 조산으로 태어나고 있습니다.
PROM은 미국에서 임신의 2-3%를 합병하고 조산의 30-40%와 관련이 있어 적절한 진단 솔루션의 중요성이 강조되고 있습니다. 이러한 이환율 증가는 새로운 진단 도구와 개입의 필요성을 강조하고 있으며, 의료진이 조산 및 관련 결과의 발생을 효과적으로 관리하고 감소시키기 위해 노력하는 가운데 시장 확대의 원동력이 되고 있습니다.
높은 검사 비용은 조산 및 PROM 검사 시장을 어느 정도 제한할 수 있습니다. 특히 자원이 부족한 국가에서는 첨단 기술 및 의료 시설의 영향을 받는 검사 비용이 상당한 장벽이 될 수 있습니다.
예를 들어, 미국에서는 조산 대응에 막대한 비용이 소요되며, 1건당 6만 5,000달러, 연간 262억 달러의 비용이 의료 시스템에 부담으로 작용합니다. 이러한 고비용은 일부 의료진과 환자들이 첨단 검사를 받는 것을 주저하게 만들 수 있습니다. 그러나 시장에서는 보다 경제적이고 비용 효율적인 검사 방법 및 기술 혁신에 대한 수요가 증가할 수 있습니다. 비용을 낮추고 접근성을 개선하기 위한 노력은 산업 전반의 성장을 지원하고 이러한 문제를 상쇄하는 데 도움이 될 수 있을 것으로 보입니다.
The preterm birth and PROM (Premature Rupture of Membranes) testing market focuses on the diagnosis and treatment of early births and membrane rupture. The growth is being driven by rising preterm birth rates and advances in diagnostic technologies. Emerging markets are growing as people become more aware of the importance of healthcare. This is likely to enable the market size to surpass USD 2.39 Billion in 2024 to reach a valuation of around USD 4.11 Billion by 2032.
Leading manufacturers in this market are developing novel tests for early detection and management. Non-invasive procedures and point-of-care diagnostics are defining the future. Demand for precise, quick findings drives market growth as healthcare professionals strive to improve patient outcomes and prevent preterm birth problems. The rising demand for Preterm Birth and Prom Testing is enabling the market grow at a CAGR of 7.76% from 2026 to 2032.
Preterm Birth and PROM Testing Market: Definition/ Overview
Preterm birth is defined as a delivery occurring before 37 weeks of pregnancy, which may result in health complications for the baby. PROM Testing Evaluation for Premature Rupture of Membranes (PROM), in which the amniotic sac ruptures before labor begins, assesses risks and guides management to avoid difficulties for both mother and baby.
Preterm birth and PROM (preterm rupture of membranes) testing aid in detecting high-risk pregnancies. Preterm birth testing determines the possibility of early labor, whereas PROM testing detects membrane rupture, which helps to prevent infections and manage preterm delivery risks. Both are critical for early intervention and better infant outcomes.
Future applications of preterm birth and PROM (Premature Rupture of Membranes) testing include increasing early detection, guiding targeted therapies and personalizing treatment approaches. To minimize preterm birth rates and related difficulties, advances will be made by combining predictive biomarkers, establishing non-invasive diagnostic procedures and revising clinical guidelines.
The rising occurrence of premature births will drive the preterm birth and PROM testing industry. In 2021, the U.S. preterm birth rate increasing to 10.5%, up from 10.1% in 2020, with almost one in every ten babies born preterm. Between 2014 and 2021, the rate climbed by 12%, with roughly 15 million babies born preterm around the world each year.
PROM complicates 2-3% of pregnancies in the United States and is connected with 30-40% of premature births, emphasizing the importance of appropriate diagnostic solutions. This rising incidence highlights the need for new diagnostic tools and interventions, which are driving market expansion as healthcare practitioners strive to effectively manage and reduce the occurrence of preterm births and related consequences.
The high cost of testing may limit the preterm birth and PROM testing market to some extent. Testing costs, which are influenced by advanced technologies and healthcare facilities, can be a considerable barrier, especially in low-resource nations.
In the United States, for example, handling premature births incurs significant costs, with each case costing $65,000 and adding to a $26.2 billion yearly burden on the healthcare system. This hefty expense may dissuade some healthcare practitioners and patients from seeking advanced testing. However, it may increase demand for more economical, cost-effective testing methods and innovations in the marketplace. Efforts to lower costs and enhance accessibility could help to offset these issues while also supporting overall industry growth.
Increasing efficacy in monitoring fetal and uterine health will drive the test type sector. Advances in technologies such as ultrasound and biomarker tests improve diagnostic accuracy, enabling for more effective care of preterm deliveries and PROM complications. Enhanced ultrasound capabilities offer more detailed images and insights into fetal development and uterine problems, resulting in better early identification and intervention techniques.
Similarly, advances in biomarker testing enable more exact identification of risk factors and illnesses. As these technologies improve in effectiveness, they are likely to gain traction and drive market expansion. The capacity to better monitor and manage pregnancy issues will result in increasing demand for advanced testing solutions, propelling the test type sector forward.
The growing number of diagnostic tests and the capacity to deliver quick clinical treatments will propel the end-user segment. Hospitals are well-positioned to profit from advances in diagnostic technologies because of their comprehensive care infrastructure, which includes access to a variety of diagnostic tests and specialists.
Hospitals are the recommended site for these services because they can perform a wide range of diagnostics, such as ultrasounds and biomarker assessments, as well as respond rapidly to preterm birth and PROM complications. As diagnostic capabilities improve and clinical interventions become more advanced, hospitals will continue to increase their use of preterm birth and PROM testing. This trend will continue to boost the end-user segment, cementing hospitals' dominance in this market.
Advanced healthcare infrastructure will fuel the market in North America, enabling the region hold major share. According to the US Department of Health and Human Services, by 2020, 96% of non-federal acute care hospitals will have implemented certified electronic health records (EHRs). Additionally, 76% of U.S. hospitals used telemedicine technologies, such as video consultations, to improve patient care and access to services.
This solid infrastructure enables the effective deployment and maintenance of modern diagnostic tests for preterm delivery and PROM. The combination of EHRs and telemedicine enhances data management, diagnostic accuracy and allows for rapid treatments. These technological developments not only improve clinical capabilities, but also promote adoption of testing solutions, resulting in market growth in North America.
The Asia Pacific region is expected to exhibit rapid growth in the preterm birth and premature rupture of membranes (PROM) testing market due to increase in healthcare investments. This growth is primarily owing to improvement in healthcare infrastructure which results in better-equipped hospitals and clinics with advanced medical technologies, enhancing the capacity for more sophisticated prenatal care and diagnostic services. Thus, access to advanced diagnostic tools improves the accuracy and timeliness of diagnoses, leading to better outcomes for mothers and infants.
Aso, providing better training and education for healthcare professionals results in improved prenatal care and reduced incidence of preterm births and PROM. In response to the need for improvement in prenatal care, there is high demand for research and development activities in diagnostic tests and treatments, such as new biomarkers or non-invasive tests.
Public health campaigns can raise awareness about the risks of preterm birth and the importance of prenatal care, leading to earlier detection and prevention strategies. Expanding healthcare coverage can make prenatal testing more accessible and affordable for a larger population, increasing the usage of PROM and preterm birth testing services.
The implementation of maternal health programs is projected to facilitate the integration of preterm birth and PROM testing into broader maternal and child health programs, leading to better preventive care and management strategies.
Furthermore, increasing healthcare investments in the Asia Pacific region are expected to significantly boost the market for preterm birth and PROM testing, improving healthcare outcomes for mothers and babies while reducing long-term healthcare costs.
The preterm birth and PROM testing market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.
Some of the prominent players operating in the preterm birth and prom testing market include:
Qiagen N.V.
Hologic, Inc.
Cooper Surgical, Inc.
Abbott
Medixbiochemica
Sera Prognostics
Clinical Innovations, LLC
Biosynex
NX Prenatal, Inc.
In May 2022, Sera Prognostics and the Newborn Foundation launched the Every Mother, Every Baby project. The purpose is to educate physicians, policymakers and public health stakeholders on the importance of validated biomarker-based preterm risk assessment tests, such as Sera's PreTRM test, in improving neonatal health outcomes maternal health outcomes.
In November 2021, Sera Prognostics has partnered with PreemieWorld, GLO Preemies and the Alliance for Black NICU Families to empower and support families affected by preterm birth.